KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $441,337 | +0.3% | 25,408 | -18.7% | 0.00% | – |
Q2 2023 | $440,070 | +64.8% | 31,255 | +25.9% | 0.00% | – |
Q1 2023 | $267,052 | -19.9% | 24,819 | +11.5% | 0.00% | – |
Q4 2022 | $333,500 | +2.9% | 22,263 | -11.7% | 0.00% | – |
Q3 2022 | $324,000 | +90.6% | 25,209 | +43.6% | 0.00% | – |
Q2 2022 | $170,000 | -12.4% | 17,555 | -10.2% | 0.00% | – |
Q1 2022 | $194,000 | -14.2% | 19,545 | +1.3% | 0.00% | – |
Q4 2021 | $226,000 | +27.0% | 19,299 | +22.5% | 0.00% | – |
Q3 2021 | $178,000 | -14.8% | 15,757 | +5.0% | 0.00% | – |
Q2 2021 | $209,000 | -35.1% | 15,005 | -13.9% | 0.00% | – |
Q1 2021 | $322,000 | -65.0% | 17,423 | -66.6% | 0.00% | – |
Q4 2020 | $921,000 | +420.3% | 52,159 | +351.0% | 0.00% | – |
Q3 2020 | $177,000 | -74.0% | 11,566 | -56.8% | 0.00% | – |
Q2 2020 | $682,000 | +163.3% | 26,771 | +60.1% | 0.00% | – |
Q1 2020 | $259,000 | +27.0% | 16,719 | -9.5% | 0.00% | – |
Q4 2019 | $204,000 | +33.3% | 18,471 | +2.6% | 0.00% | – |
Q3 2019 | $153,000 | – | 18,011 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |